Author: HealthJustfine Team

The cleanest short thesis on ResMed (NYSE: RMD) is that weight-loss drugs could shrink the obstructive sleep apnea market over time and weaken demand for PAP devices. That framing is too narrow. ResMed is not just selling initial devices into a one-time diagnosis event. It operates a broader sleep-health ecosystem built around installed devices, recurring…

Read More

This month, King’s Clinical Academic Training Office (KCATO) is collaborating with the Faculty of Dentistry, Oral & Craniofacial Sciences to spotlight clinical academics working in the field of dentistry. In this edition, we hear from Dr Sadia Niazi, Senior Clinical Lecturer/Honorary NHS Consultant in Endodontology

Read More